drugset
drugset / Trial / NCT04812067

A Safety and Efficacy Trial of TTHX1114 in People With CED

NCT04812067 ↗

Phase 2 Completed 41 enrolled Trefoil Therapeutics, Inc.
NaSingle-groupOpen-labelTreatment

Summary

Expanded access, open label study at a single dose level in patients with CED that in the opinion of the investigators might benefit from TTHX1114

Timeline

Start
2021-11-30
Primary completion
2023-08-29
Completion
2023-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject TTHX1114 Protein / enzyme biologic — Other

Indications

corneal endothelial dystrophy